Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.
A phase 3 trial of 68-Ga-NYM032 in prostate cancer, run by Norroy Bioscience Co., LTD, now recruiting.
Overview
Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer. is a phase 3 interventional study registered as NCT07615101 by Norroy Bioscience Co., LTD, with 365 participants planned, started 2026-08-06 and due to reach its primary completion in 2027-06-30. Interventions recorded: 68-Ga-NYM032.
Similar pages
not linked directly; found by shared links- TrialThis Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.
Shares PET (positron emission tomography), PET/CT, Gallium-68, Prostate cancer and the tag pipeline.
- TrialBiodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer
Shares PET (positron emission tomography), PET/CT, Gallium-68, Prostate cancer and the tag pipeline.
- TrialHER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011
Shares PET (positron emission tomography), PET/CT, Gallium-68 and the tag pipeline.
- TrialStudy of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
Shares PET (positron emission tomography), PET/CT, Prostate cancer and the tag pipeline.
- TrialA Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors
Shares PET (positron emission tomography), PET/CT and the tag pipeline.
- TrialPSMA-PET to Guide Prostatectomy
Shares PET (positron emission tomography), Prostate cancer and the tag pipeline.
- TrialA Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy
Shares Gallium-68, Prostate cancer and the tag pipeline.
- TrialA Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
Shares Gallium-68, Prostate cancer and the tag pipeline.